Abstract
TGF-βs are multifunctional polypeptides that regulate cell growth and differentiation, extracellular matrix deposition, cellular adhesion properties, angiogenesis and immune functions. In this study, we investigated the effect of TGF-β1 on liver metastasis and its mechanism by using human pancreatic cancer cell lines Panc-1, Capan-2, and SW1990. Capan-2 and SW1990 cells demonstrated enhanced liver metastatic potential by in vivo splenic injection with TGF-β1. Consequently, we examined the role of TGF-β1 on in vitro angiogenesis and received cytotoxicity by peripheral blood mononuclear leukocytes (PBMLs). While TGF-β1 slightly decreased cell proliferation, it also upregulated VEGF production in all cancer cells examined. The binding of PBMLs to cancer cells and cancer cell cytotoxicity during co-culture with PBMLs were remarkably decreased by treatment with TGF-β1. Panc-1 cells revealed no liver metastasis despite their high immunogenetic and angiogenetic abilities, which was attributed to a lack of expression of the cell surface carbohydrates that induce attachment to endothelial cells. We concluded that the presence of TGF-β1 in the microenvironment of tumour site might play an important role in enhancing liver metastasis of pancreatic cancer by modulating the capacity of angiogenesis and immunogenicity. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Brogi E, Wu T, Namiki A and Isner JM (1994) Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells. Circulation 90: 649–652
Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936–942
Damale NK (1992) Differential costimulatory effects of adhesion molecules B 7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+T lymphocytes. J Immunol 148: 1985–1992
Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S and Arkhurst RJ (1995) Defective haemetaopoiesis and vasculogenesis in transforming growth factor-β 1 knockout mice. Development 121: 1845–1854
Espevik T, Figari IS, Ranges GE and Palladino MA (1988) Transforming growth factor-β1 (TGF-β1) and recombinant human tumor necrosis factor-α reciprocally regulate the generation of lymphokine-activated killer cell activity. J Immunol 140: 2312–2316
Fidler IJ (1995) Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 21: 1588–1592
Folkman J (1995) Clinical applications of research on angiogenesis. N Engl J Med 333: 1757–1763
Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI and Korc M (1993) Enhanced expression of transforming growth factor-β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105: 1846–1856
Gorsch SM, Memoli VA, Stukel TA, Gold LI and Arrick BA (1992) Immnohistochemical staining for transforming growth factor-beta 1 associates with disease progression in human breast cancer. Cancer Res 52: 6949–6952
Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH and Kern SE (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350–353
Hiraoka T (1990) Extended radical resection of cancer of the pancreas with intraoperative radiotherapy. Clin Gastroenterol 4: 985–993
Ho JJL, Bi N, Siddiki B, Chung Y-S, Yuan M and Kim YS (1993) Multiple forms of intracellular and secreted mucins in a pancreatic cancer cell line. Cancer Res 53: 884–890
Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H and Miyake M (1999) Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79: 1553–1563
Ishii H, Gouchi A and Orita K (1994) The enhancement of cell surface ICAM-1 and HLA Class antigens in human gastric cancer cell lines by IFN-gamma. Acta Med Okayama 48: 73–79
Iwai K, Ishikura H, Kaji M, Sugiura H, Ishizu A, Takahashi C, Kato H, Tanabe T and Yoshiki T (1993) Importance of E-selectin(ELAM-1) and sialyl Lewisa in the adhesion of pancreas carcinoma cells to activated endothelium. Int J Cancer 54: 972–977
Kang SM, Maeda K, Chung YS and Sowa M (1997) Vascular endothelial growth factor expression correlates with hematogenous metastasis and prognosis in colorectal carcinoma. Oncol Reports 4: 381–384
Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB and Fauci AS (1986a) Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163: 1037–1050
Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB and Fauci AS (1986b) Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes. J Immonol 137: 3855–3860
Kim IY, Ahn HJ, Lang S, Oefelein MG, Oyasu R, Kozlowski JM and Lee C (1998) Loss of expression of transforming growth factor-β receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 4: 1625–1630
Kishimoto T, Ishikura H, Kimura C, Takahashi T, Kato H and Yoshiki T (1996) Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewisa antigen. Int J Cancer 69: 290–294
Kloen P, Gebhardt MC, Perez-Atay de A, Rosenberg AE, Springfield DS, Gold LI and Mankin HJ (1997) Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta 3 is related to disease progression. Cancer 80: 2230–2239
Maeda K, Hirakawa K, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T and Sowa M (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77: 858–863
Massague J (1990) The transforming growth factor-beta family. Ann Rev Cell Biol 6: 597–641
Mattern J, Koomagi R and Volm N (1997) Coexpression of VEGF and bFGF in human epidermoid lung cancer associated with increased vessel density. Anticancer Res 17: 2249–2252
McCulloch P, Choy A and Martin L (1995) Association between tumor angiogenesis and tumor cell shedding into effluent venous blood during breast cancer surgery. Lancet 346: 1334–1335
Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, Reali UM and Giannotti B (1997) In situ expression of transforming growth factor-beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 7: 313–321
Nishimura S, Hirakawa K, Yashiro M, Inoue T, Matsuoka T, Fujihara T, Murahashi K, Sawada T, Nakata B, Jikihara I, Takagi H and Sowa M (1998) TGF-beta 1 produced by gastric cancer cells affects mesothelial cell morphology in peritoneal dissemination. Int J Oncology 12: 847–851
Okazaki K, Nakayama Y, Shibao K, Hirata K, Nagata N and Itoh H (1998) Enhancement of metastatic activity of colon cancer as influenced by expression of cell surface antigens. J Surg Res 78: 78–84
Pepper MS (1997) Transforming growth factot-beta; vasculogenesis, angiogenesis and vessel wall integrity. Cytokine Growth Factor Rev 8: 21–43
Pertovaara L, Sistonen L, Bos TJ, Vogt PK, Keski-Oja J and Alitalo K (1989) Enhanced jun gene expression is an early genomic response to transforming growth factor β stimulation. Mol Cell Biol 9: 1255–1262
Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O and Alitalo K (1994) Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 269: 6271–6274
Rook AH, Kehrl Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC and Fauci AS (1986) Effects of transforming growth factor β on the functions of natural killer cells; Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136: 3916–3920
Sawada T, Ho JJL, Chung Y-S, Sowa M and Kim YS (1994) E-selectin binding by pancreatic tumor cells is inhibited by cancer sera. Int J Cancer 57: 901–907
Sporn MB and Roberts AB (1992) The transforming growth factor-β: recent progress and new challenges. J Cell Biol 119: 1017–1021
Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li X, Shimizu J, Fujiwara H and Hamaoka T (1991) Transforming growth factor-β-induced inhibition of T cell function. J Immunol 146: 1077–1082
Takada A, Ohmori K, Takahashi N, Tsuyuoka K, Yago A, Zenita K, Hasegawa A and Kannagi R (1991) Adhesion of human colon cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl Lewisa. Biochem Biophys Res Commun 179: 713–719
Takanami I, Tanaka F, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T and Kodaira S (1997) Transforming growth factor-beta isoforms expression in pulmonary adenocarcinomas as prognostic markers: an immunohistological study of one hundred and twenty patients. Oncology 54: 122–128
Tischer E, Mitchell R, Hartman T, Silva M, Gosp odarowicz D, Fiddes JC and Abraham JA (1991) The human gene for vascular endothelial growth factor. J Biol Chem 266: 11947–11954
Toi M, Hoshina S, Takayanagi T and Tominaga T (1994) Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85: 1045–1049
Wahl SM, McCartney-Francis N and Mehrenhagen S (1989) Inflammatory and immunomodulatory roles of TGF-β. Immunol Today 10: 258–262
Wyllie FS, Dawson T, Bond JA, Goretzki P, Game S, Prime S and Wynford-Thomas D (1991) Correlated abnormalities of transforming growth factor-β1 response and p53 expression in thyroid epithelial cell trasformation. Mol Cell Endocrinol 76: 13–21
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Teraoka, H., Sawada, T., Nishihara, T. et al. Enhanced VEGF production and decreased immunogenicity induced by TGF-β 1 promote liver metastasis of pancreatic cancer. Br J Cancer 85, 612–617 (2001). https://doi.org/10.1054/bjoc.2001.1941
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1941
Keywords
This article is cited by
-
Process of hepatic metastasis from pancreatic cancer: biology with clinical significance
Journal of Cancer Research and Clinical Oncology (2016)
-
TGFβ signaling in pancreatic ductal adenocarcinoma
Tumor Biology (2015)
-
Huachansu injection inhibits metastasis of pancreatic cancer in mice model of human tumor xenograft
BMC Complementary and Alternative Medicine (2014)
-
The anti-TNF-α antibody infliximab indirectly regulates PECAM-1 gene expression in two models of in vitro blood cell activation
Laboratory Investigation (2012)
-
Growth factor signaling in metastasis: current understanding and future opportunities
Cancer and Metastasis Reviews (2012)
